Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

279 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity.
Ananthan S, Saini SK, Zhou G, Hobrath JV, Padmalayam I, Zhai L, Bostwick JR, Antonio T, Reith ME, McDowell S, Cho E, McAleer L, Taylor M, Luedtke RR. Ananthan S, et al. Among authors: reith me. J Med Chem. 2014 Aug 28;57(16):7042-60. doi: 10.1021/jm500801r. Epub 2014 Aug 15. J Med Chem. 2014. PMID: 25126833 Free PMC article.
Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.
Brown DA, Mishra M, Zhang S, Biswas S, Parrington I, Antonio T, Reith ME, Dutta AK. Brown DA, et al. Among authors: reith me. Bioorg Med Chem. 2009 Jun 1;17(11):3923-33. doi: 10.1016/j.bmc.2009.04.031. Epub 2009 Apr 19. Bioorg Med Chem. 2009. PMID: 19427222 Free PMC article.
Structure-activity relationship study of N⁶-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N⁶-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization.
Johnson M, Antonio T, Reith ME, Dutta AK. Johnson M, et al. Among authors: reith me. J Med Chem. 2012 Jun 28;55(12):5826-40. doi: 10.1021/jm300268s. Epub 2012 Jun 13. J Med Chem. 2012. PMID: 22642365 Free PMC article.
Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine Analogues: Implication in the Treatment of Parkinson's Disease.
Das B, Vedachalam S, Luo D, Antonio T, Reith ME, Dutta AK. Das B, et al. Among authors: reith me. J Med Chem. 2015 Dec 10;58(23):9179-95. doi: 10.1021/acs.jmedchem.5b01031. Epub 2015 Nov 30. J Med Chem. 2015. PMID: 26555041 Free PMC article.
Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.
Gopishetty B, Zhang S, Kharkar PS, Antonio T, Reith M, Dutta AK. Gopishetty B, et al. Bioorg Med Chem. 2013 Jun 1;21(11):3164-74. doi: 10.1016/j.bmc.2013.03.059. Epub 2013 Apr 1. Bioorg Med Chem. 2013. PMID: 23623679 Free PMC article.
279 results